Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

This study found that Hoxc13-/- rabbits exhibit complete hair loss on the head and dorsum, providing a potential model for understanding human ECTD-9 and related dermatological conditions.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

This article reviews hirsutism, its causes, cultural perceptions, and symptoms, but provides no new clinical findings beyond existing descriptions and statistics on hair growth patterns in women.

Minoxidil can cause excessive hair growth.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

In this study, 49% of patients with alopecia areata achieved a significant response to baricitinib, with a lower baseline severity, shorter disease duration, and longer treatment duration identified as significant predictors of treatment success.

In this case report, the authors describe using Polarity Analysis for selecting homeopathic remedies to better match patient symptoms in treating alopecia areata, offering a potential alternative to corticosteroids, which are associated with significant side effects.

This article suggests that eyelash prostheses may exacerbate isotretinoin-induced blepharitis, highlighting the need for caution among young women using both products.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This study indicates that targeting the PTH/PTHrP receptor may potentially stimulate hair growth, particularly for chemotherapy-induced alopecia, as observed in hairless and cyclophosphamide-treated mice.

This review discusses the evaluation and treatment options for hirsutism, including both cosmetic and pharmacological interventions, but reports no new research findings.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study analyzed the economic burden of alopecia areata in Saudi Arabia, finding significant costs driven by productivity loss and drug expenses, with severe cases incurring higher expenses, emphasizing the need for better treatment protocols and access to therapies.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This review highlights that alopecia areata significantly impacts mental health and finances, with patients facing depression, anxiety, and substantial out-of-pocket expenses due to limited insurance coverage.

This article discusses the importance of considering biotinidase deficiency in differential diagnosis for patients with certain neurological and dermatological symptoms, as timely treatment with biotin is crucial to prevent severe consequences.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study documented clinical cases of dermatophytosis in two free-ranging southern chamois in the Eastern Pyrenees, with Trichophyton mentagrophytes identified in both animals.

This study suggests that the vitamin D receptor and hairless gene may directly regulate each other via a transcriptional mechanism, potentially explaining phenotypic similarities between atrichia and VDRRIIa rickets.

In this retrospective case series, baricitinib showed effectiveness in treating alopecia areata, with some potential benefits for psoriasis, but it may not be suitable for managing psoriatic arthritis in patients with these coexisting conditions.

This study found that group behavior therapy for trichotillomania led to greater short-term symptom improvement compared to supportive therapy, but did not achieve clinically significant changes or prevent relapse over six months.